Accueil>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Chrysomycin B

Chrysomycin B (Synonyms: Albacarcin M, Virenomycin M)

Catalog No.GC18344

La chrysomycine B est un antibiotique isolé d'une souche de Streptomyces. La chrysomycine B provoque des dommages À l'ADN dans la lignée cellulaire de l'adénocarcinome pulmonaire humain A549 et inhibe la topoisomérase II. La chrysomycine B supprime la croissance des tumeurs transplantables chez la souris.

Products are for research use only. Not for human use. We do not sell to patients.

Chrysomycin B Chemical Structure

Cas No.: 83852-56-6

Taille Prix Stock Qté
250μg
234,00 $US
En stock
1mg
556,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
Chrysomycin B is an antibiotic isolated from a strain of Streptomyces. It differs from its analog chrysomycin A by having a methyl, rather than vinyl, group in the 8-position of the chromophore. Like its analog, chrysomycin B suppresses the growth of transplantable tumors in mice, an effect that may be related to its ability to bind DNA. It also causes DNA damage in the human lung adenocarcinoma A549 cell line and inhibits topoisomerase II. Chrysomycin B is structurally very similar to gilvocarcin V, which promotes DNA cross-linking with histone 3 and GRP78 when photoactivated by near-UV light.

Avis

Review for Chrysomycin B

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Chrysomycin B

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.